Radotinib suppliers
Radotinib
- CAS:
- 926037-48-1
- MF:
- C27H21F3N8O
- MW:
- 530.5
Suppliers by country/region
Company Type
Properties
- Density
- 1.40±0.1 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- ≥26.55 mg/mL in DMSO; insoluble in EtOH; insoluble in H2O
- form
- solid
- pka
- 12.94±0.70(Predicted)
- color
- Light yellow to yellow
Safety Information
- Symbol(GHS)
GHS05,GHS07,GHS08
- Signal word
- Danger
- Hazard statements
- H302-H315-H318-H334-H317-H341-H361-H370-H335-H413
Use
Radotinib, an inhibitor of Bcr–Abl tyrosine kinase,was approved in January 2012 in Korea as a second-line treatment for chronic myeloid leukemia (CML). Radotinib is a TKI with a similar structure to the second-generation TKI, nilotinib, in which a pyridyl group has been replaced with a pyrazinemoiety. The in vitro activity of radotinib against a variety of tumor cell lines is disclosed in an issued patent. Radotinib was significantly more potent than imatinib in all of the cell lines tested. The synthesis of radotinib via amide coupling is described in the patent literature.
77 supplier list of "Radotinib"
You can find Radotinib suppliers,
manufacturers, and distributors from countries such as CHINA, United States and the United Kingdom here.
Browse to the tetrahydrofuran product information displayed by the supplier,
as well as the supplier's contact and capability information.